Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era.
Clin Cancer Res
; 26(16): 4201-4205, 2020 08 15.
Article
in English
| MEDLINE | ID: covidwho-599654
ABSTRACT
The potential immune intersection between COVID-19 disease and cancer therapy raises important practical clinical questions and highlights multiple scientific gaps to be filled. Among available therapeutic approaches to be considered, immune checkpoint inhibitors (ICI) seem to require major attention as they may act at the crossroads between cancer treatment and COVID-19 disease, due to their profound immunomodulatory activity. On the basis of available literature evidence, we suggest guidance to consider for treating physicians, and propose areas of clinical and preclinical investigation. Comprehensively, although with the necessary caution, ICI therapy seems to remain a suitable therapeutic option for patients with cancer during the COVID-19 pandemic.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Coronavirus Infections
/
Betacoronavirus
/
Antineoplastic Agents, Immunological
/
Neoplasms
Type of study:
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Language:
English
Journal:
Clin Cancer Res
Journal subject:
Neoplasms
Year:
2020
Document Type:
Article
Affiliation country:
1078-0432.CCR-20-1657
Similar
MEDLINE
...
LILACS
LIS